Safety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Phase 2 Unknown
42 enrolled
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Phase 2 Unknown
30 enrolled
BELLA
Phase 2 Unknown
31 enrolled
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Phase 2 Unknown
65 enrolled
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
Phase 2 Unknown
40 enrolled
Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC
Phase 2 Unknown
70 enrolled
Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy
Phase 2 Unknown
35 enrolled
FUTURE-SUPER
Phase 2 Unknown
139 enrolled
Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation
Phase 2 Unknown
25 enrolled
AIO-KRK-0116
Phase 2 Unknown
109 enrolled
REVOLUTION
Phase 2 Unknown
200 enrolled
RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
Phase 2 Unknown
30 enrolled
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
Phase 2 Unknown
33 enrolled
ATHENA
Phase 2 Unknown
33 enrolled
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Phase 2 Unknown
100 enrolled
INTERACT-II
Phase 2 Unknown
85 enrolled
POCHI
Phase 2 Unknown
55 enrolled
SIRTCI
Phase 2 Unknown
52 enrolled
MARIO-3
Phase 2 Unknown
91 enrolled
BEACON
Phase 2 Unknown
30 enrolled
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Phase 2 Unknown
48 enrolled
Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma
Phase 2 Unknown
22 enrolled
BRISK
Phase 2 Unknown
32 enrolled
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
Phase 2 Unknown
20 enrolled
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
Phase 2 Unknown
90 enrolled
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Phase 2 Unknown
40 enrolled
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Phase 2 Unknown
60 enrolled
The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab
Phase 2 Unknown
44 enrolled
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer
Phase 2 Unknown
20 enrolled
Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer
Phase 2 Unknown
30 enrolled
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
Phase 2 Unknown
30 enrolled
MiST
Phase 2 Unknown
186 enrolled
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
Phase 2 Unknown
30 enrolled
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
Phase 2 Unknown
87 enrolled
Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.
Phase 2 Unknown
50 enrolled
Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study
Phase 2 Unknown
33 enrolled
Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment
Phase 2 Unknown
45 enrolled
Combination of Gemcitabine, Oxaliplatin, Sintilimab and Bevacizumab in Unresectable Biliary Tract Cancer
Phase 2 Unknown
37 enrolled
Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma
Phase 2 Unknown
50 enrolled
Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer
Phase 2 Unknown
40 enrolled
Bevacizumab Plus Modiifed FOLFIRINOX in Ovarian, Fallopian Tube, or Primary Peritoneal Mucinous Carcinoma
Phase 2 Unknown
37 enrolled
Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence
Phase 2 Unknown
42 enrolled
Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
Phase 2 Unknown
12 enrolled
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer
Phase 2 Unknown
94 enrolled
Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases
Phase 2 Unknown
100 enrolled
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
Phase 2 Unknown
25 enrolled
BOLD
Phase 2 Unknown
74 enrolled
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer
Phase 2 Unknown
17 enrolled
Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer
Phase 2 Unknown
27 enrolled
Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer
Phase 2 Unknown
112 enrolled